Neonc Technologies Holdings Q3 2026 earnings

NTHI · 2026-11-05 17:00 AMC ET · 8-K on SEC

Net loss narrowed to $4.4 million as operating expenses declined to $5.8 million, supported by a $15 million equity raise.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $5.8 million (-16% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge Stock-based compensation excluded from Non-GAAP Total Operating Expenses

KPIs

MetricActualPrior quarterPrior yearChange
Net loss$4.4 million$8.6 million$8.6 million-49%
Total operating expenses$5.8 million$6.9 million$6.9 million-16%

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported.
  • EPS story Net loss narrowed due to reduced operating expenses.
  • One-off check not stated in the 8-K

The good

  • Net loss narrowed to $4.4 million from $8.6 million in Q3 2025
  • Total operating expenses declined to $5.8 million from $6.9 million in Q3 2025
  • Raised $15 million from institutional investors

The bad

  • none

The ugly

  • none

Open questions

  • How will the company fund operations beyond the $15 million raise?
  • What are the specific terms of the MoU with the Department of Health – Abu Dhabi?
Full release

Neonc Technologies Holdings (NTHI) earnings release, November 5, 2026

Neonc Technologies Holdings, Inc. (NTHI) · Form 8-K, Item 2.02 · Filed · SEC filing

NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13

CALABASAS, Calif., Nov. 05, 2026 – NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress, including the upcoming presentation of data from its NEO100 and NEO212 programs at the Society for Neuro-Oncology Annual Meeting.

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer, commented:

“The third quarter marked a period of meaningful progress for NeOnc, strengthening our clinical programs, our balance sheet and our international presence. In August, we were pleased to report positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint, an important milestone that supports the potential of our intranasal approach to directly address delivery across the blood-brain barrier, one of the greatest challenges in treating brain cancer. Additionally, during the quarter, NEO212 continued to advance toward Phase 2 development, and we look forward to sharing data from both programs at the Society for Neuro-Oncology Annual Meeting on November 13.

“Alongside these clinical achievements, we strengthened the financial and strategic foundation that supports them. In September, we raised $15 million from new and existing healthcare-focused institutional investors and used a portion of the proceeds to redeem all of our Series A Convertible Preferred Stock in cash, eliminating its potential dilution for our shareholders. At the same time, our net loss for the quarter was $4.4 million, down from $8.6 million in the third quarter of 2025, and total operating expenses declined to $5.8 million from $6.9 million.

“In October, we were honored to enter into a memorandum of understanding (MoU) with the Department of Health – Abu Dhabi to advance research and clinical capability in CNS oncology in the Emirate of Abu Dhabi. The MoU creates a framework to bring NeOnc’s development expertise together with the Emirate’s healthcare capabilities, and we are proud to work alongside the Department of Health to address the needs of patients with complex and rare brain cancers, including children.

“Finally, we were delighted to welcome Nasim Shomali and Ali Alabedin to our Board of Directors, whose expertise in corporate planning, banking and international markets deepens the Board as NeOnc grows. We thank our patients, investigators, partners and shareholders for their support, and we are encouraged by the work ahead as we strive to bring new approaches to patients with brain cancer.”

Third Quarter and Recent Highlights

Society for Neuro-Oncology Annual Meeting

NEO100 Clinical Progress

NEO212 Development

Abu Dhabi

Corporate and Financial²

Financial Results for Q3 2026³

Reconciliation of GAAP Total Operating Expenses to Non-GAAP Total Operating Expenses Excluding Stock-Based Compensation (unaudited)

About NEO100

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established.

About NEO212

NEO212 is an investigational oral conjugate of temozolomide and NEO100. It is being studied for CNS cancers, including recurrent glioblastoma. Preclinical studies support further evaluation of its potential activity and delivery characteristics; clinical efficacy and safety have not been established. NEO212 is being developed under an FDA investigational new drug application.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches.

For more information, visit https://neonc.com.

Forward-Looking Statements... (truncated)hat was not powered as a confirmatory trial, and results from compassionate use involving individual patients may not be predictive of results in clinical trials. The memorandum of understanding with the Department of Health – Abu Dhabi is not binding, and any clinical collaboration or regional activities remain subject to separate agreements and approvals. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release.⁴

The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact: info@neonc.com

Investor Contact:

Jon Nugent

Jon Nugent Communications jon@jonnugent.com

205-566-3026⁵

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Neonc Technologies Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.